A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score
Open Access
- 22 September 2023
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (11) , 2310-2322
Abstract
The Mayo Clinical Score is used in clinical trials to describe the clinical status of patients with ulcerative colitis (UC). It comprises four subscores: rectal bleeding (RB), stool frequency (SF), physician's global assessment, and endoscopy (ENDO). According to recent US Food and Drug Administration guidelines (Ulcerative colitis: developing drugs for treatment, Guidance Document, https://www.fda.gov/regulatory‐information/s. 2022), clinical response and remission should be based on modified Mayo Score (mMS) relying on RB, SF, and ENDO. Typically, ENDO is performed at the beginning and end of each phase, whereas RB and SF are more frequently available. Item response theory (IRT) models allow the shared information to be used for prediction of all subscores at each observation time; therefore, it leverages information from RB and SF to predict ENDO. A UC disease IRT model was developed based on four etrolizumab phase III studies to describe the longitudinal mMS subscores, placebo response, and remission at the end of induction and maintenance. For each subscore, a bounded integer model was developed. The placebo response was characterized by a mono‐exponential function acting on all mMS subscores similarly. The final model reliably predicted longitudinal mMS data. In addition, remission was well‐predicted by the model, with only 5% overprediction at the end of induction and 3% underprediction at the end of maintenance. External evaluation of the final model using placebo arms from five different studies indicated adequate performance for both longitudinal mMS subscores and remission status. These results suggest utility of the current disease model for informed decision making in UC clinical development, such as assisting future clinical trial designs and evaluations.Keywords
This publication has 27 references indexed in Scilit:
- Long-term outcomes of colectomy surgery among patients with ulcerative colitisSpringerPlus, 2015
- Clinical Trials in Ulcerative Colitis: A Historical PerspectiveJournal of Crohn's and Colitis, 2015
- Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric ModelingPharmaceutical Research, 2014
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Abatacept for Crohn's Disease and Ulcerative ColitisGastroenterology, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Female gender and surgery impair relationships, body image, and sexuality in inflammatory bowel diseaseInflammatory Bowel Diseases, 2009
- A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative ColitisGastroenterology, 2007
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEMComputer Methods and Programs in Biomedicine, 2005